BURLINGTON, Mass., Nov. 13, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that ultra-orphan drug specialists are among the lowest value for money for pharmaceutical companies seeking to boost their top-line sales via M&A. The Strategic Insights report entitled How to Spend it: Buy-out Targets Every Pharma Company Should Consider finds that only one biotech specializing in orphan drugs is expected to garner 2019 sales that strongly support its multi-billion dollar purchase price.
Decision Resources valuation methodology, which—in the context of the target market—takes into account price versus projected sales, finds that there is better value in small diversified companies or for companies with pipeline drugs that are being lined up to slot into the future therapeutic landscape of an indication.
"Drugs for rare diseases have huge sales potential, carry premium prices and have minimal competition," said Decision Resources Senior Analyst Lisa Murch. "However, these benefits are obvious to investors, and the share prices for companies with strong candidates in the pipeline are sky high. This leaves no room to account for the still-considerable risk of R&D, not to mention the possibility of pressure on these very high drug prices."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources